

Date of preparation: 22 April 2026

Issuer's abbreviated name: SYN2BIO SA

Current report: 12/2026 ESPI

Subject: Execution of the final treasury (founders') share purchase agreement by the Company

Legal basis: Article 56 Section 1 Item 2 of the Act on Offerings – current and periodic information

Body of the report:

Time of publication: 2:19 p.m.

The Management Board of the company doing business as SYN2BIO Spółka Akcyjna with its registered office in Warsaw, entered in the register of businesses in the National Court Register kept by the District Court for the capital city of Warsaw in Warsaw, 13th Commercial Division of the National Court Register under file number KRS: 0001186962, holding Taxpayer Identification Number: 5214128214, REGON statistical number: 542419239 (hereinafter referred to as the “Company”) hereby reports that on 22 April 2026 the Company executed the final share purchase agreement pursuant to which 200,000 ordinary bearer series A shares numbered from 000,001 to 200,000 with a nominal price of PLN 0.50 (say: fifty grosz) each and a total nominal price of PLN 100,000.00 (say: one hundred thousand) designated by the National Securities Depository (KDPW SA) with the ISIN code: PLSNBIO00013, representing 2.29% of the Company's share capital were purchased.

The final share purchase agreement was executed to perform the preliminary agreement of 18 February 2026 whereby the Company agreed to purchase shares from shareholders: Ms. Anna Szymańska and Mr. Cezary Kozanecki. The preliminary agreement is described in the prospectus approved by the Polish Financial Supervision Authority on 12 March 2026. The share purchase was carried out at the nominal share price (50 grosz per share), and thus for a total amount of PLN 100,000. The company thereby purchased treasury shares by entering into this final agreement.

The treasury shares in question are the Company's founders' shares, which are purely technical in nature, making it possible to conduct the demerger of Synektik SA, where the intent of the Company and Synektik SA was to precipitate a situation in which the Company's shareholder composition following the demerger is in principle identical to the shareholder composition of Synektik SA. Accordingly, the acquired shares are designated to be retired, which will transpire at the next shareholder meeting.

Representatives of the Issuer:

Cezary Kozanecki - President of the
Management Board